stockrowBioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
Follow BCRX
Alert me
BioCryst Pharmaceuticals, Inc. (BCRX) Shares outstanding
BioCryst Pharmaceuticals, Inc.'s shares outstanding at the end of fiscal 2025 was $218.6M, up 5.75% from $206.7M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $267.6M. Over the past ten years it has ranged from $72.9M (fiscal 2015) to $218.6M (fiscal 2025) — the current reading is the highest in ten years. BioCryst Pharmaceuticals, Inc. ranks 14th of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $218.6M | 5.75% |
| FY2024 | $206.7M | 7.54% |
| FY2023 | $192.2M | 3.38% |
| FY2022 | $185.9M | 3.79% |
| FY2021 | $179.1M | 7.08% |
| FY2020 | $167.3M | 44.69% |
| FY2019 | $115.6M | 12.03% |
| FY2018 | $103.2M | 22.18% |
| FY2017 | $84.5M | 14.59% |
| FY2016 | $73.7M | 1.09% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $267.6M | 0.93% |
| Jun 2026 | $265.2M | 9.46% |
| Mar 2026 | $242.3M | 10.83% |
| Dec 2025 | $218.6M | (0.59%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ALVO Alvotech compare | $295.0M |
| BCRX BioCryst Pharmaceuticals, Inc. | $267.6M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $214.3M |
| TRLV Trulieve Cannabis Corp. compare | $200.6M |
| XERS Xeris Biopharma Holdings, Inc. compare | $189.9M |
| PRGO Perrigo Company plc compare | $139.4M |
| PBH Prestige Consumer Healthcare Inc. compare | $47.6M |
| ANIP ANI Pharmaceuticals, Inc. compare | $21.7M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on BCRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement